Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive results of two Phase III studies show VEGF Trap-Eye candidate has potential for dosing every two months, but competing against Roche's Lucentis and off-label Avastin won't be easy.

You may also be interested in...



Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution

As Sanofi/Genzyme plans to take leukemia drug Campath out of the commercial market in the U.S. and Europe so it will not undercut sales of the same compound in a different indication, patient advocates are confident that a patient-access system will continue providing the drug to those who need it.

Eylea's Dosing Regimen Is Key Question As FDA Takes Draft Labeling To Advisory Committee

Advisory panel to consider a bi-monthly dosing scheme for Regeneron's wet AMD and how to handle potential elevations in intraocular pressure at June 17 meeting.

Eylea's Dosing Regimen Is Key Question As FDA Takes Draft Labeling To Advisory Committee

Advisory panel to consider a bi-monthly dosing scheme for Regeneron's wet AMD and how to handle potential elevations in intraocular pressure at June 17 meeting.

Related Content

Topics

UsernamePublicRestriction

Register

PS071485

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel